Product Description
MNK-795 is an investigational, extended-release oral formulation of oxycodone and acetaminophen that has been studiedfor the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate.
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mallinckrodt
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Pain, Postoperative|Osteoarthritis|Low Back Pain|Bunion
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| COV15000182 | P3 |
Completed |
Pain, Postoperative|Bunion |
2012-08-01 |
|
| COV15000181 | P3 |
Completed |
Osteoarthritis|Low Back Pain |
2012-06-18 |